Pfizer stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the situation it has created. Deeply concerned by the human suffering we all are witnessing during the ongoing crisis in Ukraine, Pfizer is committed to ensuring the safety of our colleagues and their families while also facilitating continued access to our medicines for patients in need across the region.

Pfizer’s operations in Russia remain focused on the continued provision of our medicines and vaccines to patients in need across the country, in compliance with applicable laws and regulations. We have concluded that any voluntary pause in the flow of our medicines to Russia would be in direct violation of our foundational principle to put patients first.

However, maintaining the supply of medicines to Russia does not mean we will continue doing business as usual in Russia. The decisions we have taken include:

1. Pfizer is donating all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine. This is in addition to all other recently announced donations from Pfizer to Ukraine. To date, more than $22 million has been donated through The Pfizer Foundation to causes supporting the Ukrainian people;
2. We will no longer initiate new clinical trials in Russia, and we will stop recruiting new patients in our ongoing clinical trials in the country. Pfizer will work with FDA and other regulators to transition all ongoing clinical trials to alternative sites outside Russia. Consistent with our commitment to putting patients first, we will continue providing needed medicines to the patients already enrolled in clinical trials;
3. And, while Pfizer doesn’t own or operate any manufacturing sites in Russia, we will cease new investments with local suppliers intended to build manufacturing capacity in the country.

You can find further information about our response to this crisis on our website: How Pfizer is Responding to the Crisis in Ukraine | Pfizer .

Maintaining the well-being of our colleagues while ensuring the continuous supply of medicines to patients is our first priority. Pfizer also has a cross-functional team of people dedicated to maintaining the safety and well-being of our colleagues, and we are continuously assessing the risks to the most vulnerable.